Skip to main content
Livermore
Livermore
US stocksTW
ZHEN

Afeyan Noubar's Form 4 filing

Codiak BioSciences, Inc.CDAK · filed Sep 16, 2022

Accession no.
0000899243-22-031404
Filed
Sep 16, 2022, 7:30 PM ET
Trade date
Sep 15, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 2 derivative transactions. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Afeyan NoubarCIK 000122201210% Owner
Flagship Ventures Fund V, L.P.CIK 000162763910% Owner
Flagship Ventures Fund V General Partner LLCCIK 000172457510% Owner
Flagship V VentureLabs Rx Fund, L.P.CIK 000172493910% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 15, 2022Common StockPPurchaseAcquired+722,590–F1–1,865,767Indirect
Sep 15, 2022Common StockPPurchaseAcquired+210,743–F1–1,188,920Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 15, 2022Common StockPPurchaseAcquired+722,590–F1–722,590Indirect
Sep 15, 2022Common StockPPurchaseAcquired+210,743–F1–210,743Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On September 15, 2022, pursuant to an underwritten public offering by the Issuer (the "Offering"), Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 722,590 shares of Common Stock and accompanying warrants to purchase 722,590 shares of Common Stock, and Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx") acquired 210,743 shares of Common Stock and accompanying warrants to purchase 210,743 shares of Common Stock. The combined purchase price in the Offering was $1.50 per share of Common Stock and accompanying warrant.

Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)